R&D Systems™ Recombinant Human CD58/LFA-3 Fc Chimera Protein

Description

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

The Recombinant Human CD58/LFA-3 Fc Chimera Protein is derived from HEK293. The Recombinant Human CD58/LFA-3 Fc Chimera Protein has been validated for the following applications: Bioactivity.

Specifications

• Accession Number: P19256
• For Use With (Application): Bioactivity
• Gene ID (Entrez): 965
• Molecular Weight (g/mol): 48 kDa
• Quantity: 50 μg
• Source: Human embryonic kidney cell,HEK293-derived human CD58/LFA-3 protein, (N-terminus) Human CD58 (Phe29-Arg215) Accession &Num; P19256 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Regulatory Status: RUO
• Endotoxin Concentration: <0.10 EU per 1 μg of the protein by the LAL method.
• Specific Reactivity: CD58/LFA-3
• Conjugate: Unconjugated
• Species: Human
• Recombinant: Recombinant
• Reconstitution: Reconstitute at 400 μg/mL in PBS.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity or Quality Grade: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.